Cholesterol is a fatty substance manufactured by the body (mainly the liver) which plays a vital role in functioning of cell membranes. Hypercholesterolaemia is the presence of raised or abnormal levels of cholesterol in the blood. Cholesterol levels are found in a continuum within a population. Higher total cholesterol levels lead to increased risk of cardiovascular disease (CVD). Lowering cholesterol is effective for both primary and secondary prevention of all forms of CVD.
Get full access to this article
View all access options for this article.
References
1.
4S Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet (1994) 344: p. 1383–9
2.
ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361: p. 1149–58
3.
BaigentC., KeechA., KearneyP.M.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366: p. 1267–78
4.
BhatnagarD., SoranH., DurringtonP.N.Clinical review. Hypercholesterolaemia and its management. British Medical Journal (2008) 337: p. a993
5.
British National Formulary 57 (2009) Accessed via www.bnf.org [date last accessed 16.08.2009]
6.
CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364: p. 685–96
Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. Diabetes Care (2001) 24: 1335–41. Accessed via care.diabetesjournals.org/content/24/8/1335.full.pdf+html [date last accessed 26.08.2009]
9.
DunnN., EverittH., SimonC.Oxford General Practice Library: cardiovascular problems (2007) Oxford: Oxford University Press ISBN: 978-0-19-923538-4
10.
EmbersonJ.R., WhincupP.H., MorrisR.W., WalkerM.Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. European Heart Journal (2003) 24 (19): p. 1719–26
11.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360: p. 7–22
12.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin of 5963 people with diabetes: a randomized placebo-controlled trial. Lancet (2003) 362: p. 2005–16
13.
Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery (2007) 45 (4): p. 645–54
14.
JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice (2005) Accessed via www.bcs.com/download/651/JBS2final.pdf [date last accessed 09.06.2009]
15.
MercuriM., BondM.G., SirtoriC.R.Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Lipid modification Atherosclerosis Italian Ultrasound Study. American Journal of Medicine (1996) 101 (6): p. 627–34
16.
National Statistics. Health statistics quarterly (2007) Accessed via www.statistics.gov.uk/downloads/ [date last accessed 09.06.2009]
NICE CG67Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (2008) Accessed via www.nice.org.uk/nicemedia/pdf/CG67FullGuideline1.pdf [date last accessed 26.08.2009]
PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360: p. 1623–30
SIGN Risk estimation and the prevention of cardiovascular disease (2007) Accessed via www.sign.ac.uk/pdf/sign97.pdf [date last accessed 26.08.2009]
26.
SimonC., EverittH., van DorpF.Oxford Handbook of General Practice (3rd edition) (2009) USA: Oxford University Press ISBN: 978-0-19-923610-7
27.
West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine (1995) 333 (20): p. 1301–7
